Evommune to Present at the 2021 American College of Toxicology Annual Meeting and the Annual Dermatology Drug Development Summit for Inflammatory Diseases
LOS ALTOS, Calif., Nov. 16, 2021 /PRNewswire/ -- Evommune, Inc. a private R&D company and innovation engine in chronic inflammation, today announced that Hans Hofland, senior vice president, research, will present at the 42nd Annual Meeting of the American College of Toxicology and the 5th Annual Dermatology Drug Development Summit for Inflammatory Diseases this week.
"I look forward to sharing our perspective on a variety of unique models we utilize at Evommune in our research of potential treatments for inflammatory diseases as well as strategies we are implementing to help de-risk clinical development," said Dr. Hofland. "I'm excited to discuss how we are using the skin to help us accelerate drug development, including the use of our novel screening platform approach to ensure we identify molecules that are differentiated and will have the best impact for patients."
2021 American College of Toxicology Annual Meeting
Dermatology Drug Development Summit for Inflammatory Diseases
Only registered attendees of each conference will be able to view the presentations.
About Evommune, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/evommune-to-present-at-the-2021-american-college-of-toxicology-annual-meeting-and-the-annual-dermatology-drug-development-summit-for-inflammatory-diseases-301424822.html
SOURCE Evommune, Inc.